profit from every $100 of sales.
$0$100
LifeMD
$19.97+7.42% today
-16.6% in 1 year
1-year low $18.591-year high $24.01
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What LifeMD sold, what it kept, and what it did with the cash.
Sales went from $119 million in 2022 to $194 million in 2025, with $14.4 million of profit last year.
SalesProfit
LifeMD vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| LifeMD | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads LifeMD's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 119 | 153 | 155 | 194 | |
| 100 | 134 | 133 | 166 | |
| -40 | -14 | -20 | -8 | |
| -36 | -8 | -14 | -2 | |
| -46 | -21 | -21 | 14 | |
| – | – | – | – | |
| 84.3% | 87.6% | 86.2% | 85.7% | |
| -33.3% | -9.5% | -13.2% | -4.0% | |
| -38.3% | -13.5% | -13.8% | 7.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 26 | 58 | 76 | 70 |
| Cash | 4 | 33 | 33 | 37 |
| Total debt | 4 | 19 | 25 | 6 |
| Total liabilities | 33 | 53 | 84 | 47 |
| -7 | 4 | -9 | 23 | |
| – | – | – | – | |
| – | -51.0% | -101.7% | -23.7% | |
| 666.7% | -587.6% | 235.7% | 62.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | 9 | 18 | 8 | |
| 13 | 9 | 8 | 10 | |
| -36 | 0 | 9 | -1 | |
| Dividends paid | 3 | 3 | 3 | 3 |
| – | – | – | – | |
| 14 | 12 | 12 | 10 |
Valuation
- –
- –
- 0.12
- 13.4×
- 0.9×
- 13.9×
- –
- 4.0%
- -8.1%
- 0.0%
Profitability
- 85.7%
- -4.0%
- 7.4%
- -2.0%
- -60.8%
- 252.1%
- -172.3%
- -23.2%
- -62.8%
- 3.4%
Growth
- +17.7%
- –
- +7.2%
- –
- +13.7%
Financial health
- -20.1×
- 0.41
- 8.8%
- -13.9×
- 1.04
- 0.98
- 3.13
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 952
Bottom 18%of 884
Top 31%of 886
Top 29%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.20 | -0.21 | +2.8% |
| Mar 9, 2026 | 0.41 | -0.07 | +724.0% |
| Nov 17, 2025 | -0.08 | -0.02 | −312.2% |
| Aug 5, 2025 | -0.05 | -0.01 | −461.0% |
| May 6, 2025 | 0.03 | -0.05 | +162.1% |
| Mar 10, 2025 | -0.00 | – | – |
| Nov 7, 2024 | -0.14 | – | – |
| Aug 7, 2024 | -0.17 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
26No pass
Philip Fisher
42No pass
Peter Lynch
73Pass
Joel Greenblatt
4No pass
Charlie Munger
37No pass
Terry Smith
36No pass
Questions about LifeMD
Is LifeMD a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the LifeMD AI analysis
What does LifeMD do?
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. It is in Medical - Pharmaceuticals.
Does LifeMD pay a dividend?
Yes. In 2025 it paid out $3.11 million in dividends.
How has LifeMD stock done over the past year?
Down 16.6% over the past twelve months, to $19.97. It traded between $18.59 and $24.01 and is 16.8% below its high.
Who are LifeMD's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with LifeMD's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.